Joseph Shulman - 01 Feb 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: Chief Technical Officer
Signature: /s/ Hunter Smith, attorney-in-fact for Joseph Shulman
Issuer symbol: RYTM
Transactions as of: 01 Feb 2024
Net transactions value: -$59,659
Form type: 4
Filing time: 05 Feb 2024, 18:54:08 UTC
Previous filing: 29 Dec 2023
Next filing: 13 Nov 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RYTM	Common Stock	Options Exercise		+3,938			3,938	01 Feb 2024	Direct	F1
transaction	RYTM	Common Stock	Sale	$59,659	-1,324	-34%	$45.06	2,614	01 Feb 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RYTM	Restricted Stock Units	Options Exercise	$0	-3,938	-25%	$0.000000	11,812	01 Feb 2024	Common Stock	3,938		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2	The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3	The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.